Dramatic response to regorafenib in early glioblastoma progression: case report and review of the literature.
Sign Up to like & getrecommendations! Published in 2022 at "European review for medical and pharmacological sciences"
DOI: 10.26355/eurrev_202207_29287
Abstract: BACKGROUND Glioblastoma (GBM) is a highly lethal disease despite integrated treatment comprising radiotherapy plus concomitant and adjuvant temozolomide, with a median overall survival of less than 15 months. For recurrent glioblastoma, there is yet no… read more here.
Keywords: glioblastoma; response regorafenib; case report; regorafenib early ... See more keywords
Characterization of Glioblastoma Cells Response to Regorafenib
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14246193
Abstract: Simple Summary Glioblastoma is the most aggressive primary brain tumor, characterized by a short survival and by an invariably poor outcome. The clinical management of glioblastoma patients is based on surgery followed by adjuvant radio-chemotherapy.… read more here.
Keywords: glioblastoma; response regorafenib; regorafenib; cells response ... See more keywords